Faculty & Scientific Staff
James Lord, MD, PhD
Background Information
James Lord received his PhD in Immunology through the University of Washington, Fred Hutchinson Cancer Research Center and Benaroya Research Institute (BRI). He subsequently completed his MD at the University of Washington, where he remained for his internal medicine residency and clinical research fellowship in gastroenterology. During his fellowship, he returned to BRI to pursue a research project in the lab of Steven Ziegler, PhD, exploring the role of FOXP3+ regulatory T cells (Tregs) in the pathogenesis of human inflammatory bowel disease (IBD). He joined Virginia Mason Medical Center (VMMC) in 2010 and has established his clinical practice at the Digestive Disease Institute, specializing in the care of patients with IBD.
Area of Research
Dr. Lord continues to explore cells of the mucosal immune system in patients with IBD. He has compiled an extensive archive of research materials and data from the blood and intestinal tissue of patients with and without IBD since 2006. Using these materials, he is now actively comparing the characteristics of circulating and mucosal immune cells in terms of their composition, expression of immunoregulatory molecules and cytokine signal transduction capabilities and correlating his findings with clinical characteristics and genetic risk factors for IBD. This work is complemented by investigation of how other mucosal immune cells, such as dendritic cells, may influence the inhibitory potential of Tregs in functional assays.
Featured Publications
-
Mar 2022
MAdCAM-1 Costimulates T Cells through Integrin α(4)β(7) to Cause Gene Expression Events Resembling Costimulation through CD28.
ImmunohorizonsDeBerg HA, Konecny AJ, Shows DM, Lord JD -
Jan 2020
Escherichiacoli-Specific CD4+ T Cells Have Public T-Cell Receptors and Low Interleukin 10 Production in Crohn's Disease.
Cell Mol Gastroenterol HepatolUchida AM, Boden EK, James EA, Shows DM, Konecny AJ, Lord JD -
Nov 2018
High-dimensional immune phenotyping and transcriptional analyses reveal robust recovery of viable human immune and epithelial cells from frozen gastrointestinal tissue.
Mucosal ImmunolKonnikova L, Boschetti G, Rahman A, Mitsialis V, Lord J, Richmond C, Tomov VT, Gordon W, Jelinsky S, Canavan J, Liss A, Wall S, Field M, Zhou F, Goldsmith JD, Bewtra M, Breault DT, Merad M, Snapper SB, Lord JD -
Sep 2018
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Dig Dis SciBoden EK, Shows DM, Chiorean MV, Lord JD -
Aug 2018
Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Clin ImmunolLord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH